ChromaCode Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
65
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$38M
- Investors
-
13
ChromaCode General Information
Description
Developer of a molecular diagnostics technology designed to connect patients to the right treatment through smarter, more accessible diagnostics. The company's technology blends signal processing and tailored chemistry to allow for multiplexed, low-cost chemistry that integrates into existing laboratory workflows, enabling laboratories to carry out cost-effective testing of multiple targets in a single sample on common, existing quantitative polymerase chain reaction instrumentation.
Contact Information
Website
www.chromacode.comCorporate Office
- 2330 Faraday Avenue
- Suite 100
- Carlsbad, CA 92008
- United States
Corporate Office
- 2330 Faraday Avenue
- Suite 100
- Carlsbad, CA 92008
- United States
ChromaCode Timeline
ChromaCode Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series D) | 27-Feb-2023 | $38M | Completed | Generating Revenue | ||
| 4. Grant | 16-Mar-2021 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 03-Dec-2020 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series B) | 25-Apr-2017 | $12M | $14.2M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A1) | 13-Aug-2015 | $2.2M | $2.2M | Completed | Generating Revenue |
ChromaCode Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D-2 | ||||||||
| Series D-1 | ||||||||
| Series C | ||||||||
| Series B | 17,251,462 | $0.000100 | $0.06 | $0.7 | $0.7 | 1x | $0.7 | 9.53% |
| Series A1 | 10,805,082 | $0.000100 | $0.02 | $0.24 | $0.24 | 1x | $0.24 | 5.97% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
ChromaCode Comparisons
Industry
Financing
Details
ChromaCode Competitors (8)
One of ChromaCode’s 8 competitors is Medrio, a Venture Capital-Backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Medrio | Venture Capital-Backed | San Francisco, CA | ||||
| Pleno | Venture Capital-Backed | San Diego, CA | ||||
| MedNet (Healthcare Technology Systems) | Venture Capital-Backed | Minnetonka, MN | ||||
| Biofidelity. | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Bio-Rad Laboratories | Corporation | Hercules, CA |
ChromaCode Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ChromaCode Patents
ChromaCode Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240392359-A1 | Detection of donor dna in transplant recipient bio-sample | Pending | 11-May-2023 | ||
| EP-4381097-A1 | Methods, systems and compositions for detection of multiple analytes | Pending | 06-Aug-2021 | ||
| GB-2626866-A | Methods, systems and compositions for detection of multiple analytes | Pending | 06-Aug-2021 | ||
| US-20240352508-A1 | Methods, systems and compositions for detection of multiple analytes | Pending | 06-Aug-2021 | ||
| US-20240247323-A1 | Multiplexed pcr assay with point of care sample | Pending | 14-Apr-2020 | C12Q1/701 |
ChromaCode Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ChromaCode Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Global Brain | Venture Capital | Minority | ||
| Shimadzu | Corporation | Minority | ||
| Vensana Capital | Venture Capital | Minority | ||
| XPRIZE | Other | |||
| Adjuvant Capital | Impact Investing | Minority |
ChromaCode FAQs
-
When was ChromaCode founded?
ChromaCode was founded in 2012.
-
Where is ChromaCode headquartered?
ChromaCode is headquartered in Carlsbad, CA.
-
What is the size of ChromaCode?
ChromaCode has 65 total employees.
-
What industry is ChromaCode in?
ChromaCode’s primary industry is Diagnostic Equipment.
-
Is ChromaCode a private or public company?
ChromaCode is a Private company.
-
What is the current valuation of ChromaCode?
The current valuation of ChromaCode is .
-
What is ChromaCode’s current revenue?
The current revenue for ChromaCode is .
-
How much funding has ChromaCode raised over time?
ChromaCode has raised $97.2M.
-
Who are ChromaCode’s investors?
Global Brain, Shimadzu, Vensana Capital, XPRIZE, and Adjuvant Capital are 5 of 13 investors who have invested in ChromaCode.
-
Who are ChromaCode’s competitors?
Medrio, Pleno, MedNet (Healthcare Technology Systems), Biofidelity., and Bio-Rad Laboratories are some of the 8 competitors of ChromaCode.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
